留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

群体药动学应用于个体化给药的研究进展

林艳

林艳. 群体药动学应用于个体化给药的研究进展[J]. 药学实践与服务, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
引用本文: 林艳. 群体药动学应用于个体化给药的研究进展[J]. 药学实践与服务, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
Citation: LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

Research progress of population pharmacokinetics applying to individualized medication

  • 摘要: 群体药动学运用经典的药动学原理结合统计学方法,以稀疏数据预测患者血药浓度,可达到监测药物体内过程和指导临床个性化给药的目的。查阅近年来的相关文献,结合实例综述群体药动学应用于治疗窗窄的药物、个体差异大的药物、联合用药、特殊人群用药等方面的最新进展,为其深入研究和指导临床用药提供参考。
  • [1] 倪天庆, 胡思源, 司端运, 等. 中药儿童群体药动学试验设计要点[J]. 中草药, 2013, 44(021): 3089-3091.
    [2] 张 弨, 翟所迪. 群体药动学在治序药物监测中的应用[J]. 临床药物治疗杂志, 2006, 4(1): 45-50.
    [3] 蒋新国.生物药剂学与药物动力学[M]. 北京: 高等教育出版社, 2009: 538-540.
    [4] Tatarinova T, Neely M, Bartroff J, et al.Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian[J].J Pharmacokinet Pharmacodyn, 2013, 40(2): 189-199.
    [5] Wakefield J, Walker S. Bayesian nonparametric population models: formulation and comparison with likelihood approaches[J].J Pharmacokinet Biopharm, 1997, 25(2): 235-253.
    [6] Rosner GL, Muller P. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models[J].J Pharmacokinet Biopharm, 1997, 25(2): 209-233.
    [7] 林翠鸿, 王长连, 柯 蒙. 群体药动学及其在个体化给药中的应用[J].中国临床药学杂志, 2005,14(01): 58-60.
    [8] Schaeftlein A, Minichmayr IK, Kloft C. Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data[J].Eur J Pharm Sci, 2014,57:68-73.
    [9] Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy[J].Ther Drug Monit, 2012, 34(4): 368-371.
    [10] 胡 敏, 张静华, 孙 鹤, 等. 群体药动学原理及NONMEM法数据分析[J].药学服务与研究, 2002,2(4): 227-230.
    [11] Sherwin CM, Kiang TK, Spigarelli MG, et al. Fundamentals of population pharmacokinetic modelling: validation methods[J].Clin Pharmacokinet, 2012, 51(9): 573-590.
    [12] Krauss M, Burghaus R, Lippert JOR, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification[J].In Silico Pharmacology, 2013, 1(1): 1-11.
    [13] Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J].Clin Pharmacokinet, 2004, 43(10): 623-653.
    [14] Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients—population pharmacokinetic approach[J].Eur J Pharm Sci, 2013, 52: 34-40.
    [15] Seng KY, Hee KH, Soon GH, et al. CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients[J].J Clin Pharmacol, 2014, 54(2):215-224.
    [16] Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type[J].J Clin Pharm Ther, 2009, 34(4): 473-483.
    [17] 翁芳娟. 万古霉素的群体药动学研究[J].海峡药学, 2013,25(7): 207-209.
    [18] N PP, D BBF. The epilepsy prescriber's guide to antiepileptic drugs[M].Oxford: Cambridge University Press, 2010.
    [19] Jovanovic M, Sokic D, Grabnar I, et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling[J].Eur J Pharm Sci, 2013, 50(3-4): 282-289.
    [20] Marsot A, Boulamery A, Bruguerolle B, et al. Population pharmacokinetic analysis during the first 2 years of life: an overview[J].Clin Pharmacokinet, 2012, 51(12): 787-798.
    [21] Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?[J].Int J Antimicrob Agents, 2013, 41(6): 564-568.
    [22] Conil JM, Georges B, Fourcade O, et al. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration[J].Int J Clin Pharmacol Ther, 2007, 45(3): 133-142.
    [23] Conil JM, Georges B, Ravat F, et al. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations[J].Clin Ther, 2013, 35(10): 1603-1612.
    [24] 柳晓泉, 陈渊成, 郝 琨, 等. 药动学一药效学结合模型的研究进展及在新药研发中的应用[J].中国药科大学学报, 2007, 38(6): 481-488.
    [25] 王 清, 朱萱萱, 周 杰, 等. 参麦注射液在心肌缺血患者体内的群体药动学研究[J].中华中医药学刊, 2013,31(12): 2702-2705.
    [26] Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral formulation[J].Biodrugs, 2001, 15(5): 279-290.
    [27] Yoshida K, Kimura T, Hamada Y, et al. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from sandimmune to neoral in stable renal transplant patients[J].Transplant P, 2001, 33(7): 3146-3147.
    [28] Yue CS, Huynh HH, Raymond C, et al. Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers[J].J Pharm Pharm Sci, 2013, 16(1): 89-98.
    [29] Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil[J].J Clin Pharmacol, 2013, 53(1): 29-40.
  • [1] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [2] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
  • 加载中
计量
  • 文章访问数:  3810
  • HTML全文浏览量:  403
  • PDF下载量:  867
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-07-18
  • 修回日期:  2015-03-14

群体药动学应用于个体化给药的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.002

摘要: 群体药动学运用经典的药动学原理结合统计学方法,以稀疏数据预测患者血药浓度,可达到监测药物体内过程和指导临床个性化给药的目的。查阅近年来的相关文献,结合实例综述群体药动学应用于治疗窗窄的药物、个体差异大的药物、联合用药、特殊人群用药等方面的最新进展,为其深入研究和指导临床用药提供参考。

English Abstract

林艳. 群体药动学应用于个体化给药的研究进展[J]. 药学实践与服务, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
引用本文: 林艳. 群体药动学应用于个体化给药的研究进展[J]. 药学实践与服务, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
Citation: LIN Yan. Research progress of population pharmacokinetics applying to individualized medication[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 293-297,346. doi: 10.3969/j.issn.1006-0111.2015.04.002
参考文献 (29)

目录

    /

    返回文章
    返回